Nigeria has officially expanded its arsenal against HIV with the introduction of Long-Acting Injectable Lenacapavir (LEN) PrEP, a breakthrough biomedical intervention designed to provide sustained protection for high-risk individuals.
The announcement, made by the Federal Ministry of Health and Social Welfare, marks a strategic shift toward more flexible and effective prevention methods within the country’s healthcare system.
A New Frontier in Prevention
The rollout is being spearheaded by the National AIDS, Viral Hepatitis and STIs Control Programme (NASCP). Unlike daily oral pills, which can be difficult for some to maintain, this long-acting injectable offers a discreet and convenient alternative that ensures prolonged protection without the burden of a daily regimen.
By integrating Lenacapavir into the national framework, the Ministry aims to significantly improve adherence rates among populations most vulnerable to infection.
Strengthening the National Response
Health officials view this addition as a cornerstone of the revised national strategy. The introduction of LEN PrEP is expected to bridge the gap for individuals who face barriers to traditional prevention methods, such as stigma or pill fatigue.
“This is another important step in Nigeria’s journey toward ending HIV as a public health threat,” as posted on X. “By expanding prevention choices, we are strengthening our response and ensuring that no one is left behind in our mission to achieve a zero-infection future.”
Closing the Gap on Public Health Goals
Nigeria continues to be a focal point for global HIV targets. The addition of Lenacapavir aligns with international goals to reduce new infections through innovative medical technology.
The Ministry’s commitment to diversifying prevention options underscores a proactive approach to public health, moving the nation closer to the ambitious goal of eliminating HIV as a major health concern by the end of the decade.
Share this
